In the evolving landscape of life sciences, the integration of AI into compliance frameworks is becoming critical for success.
Tarini Mohapatra, CEO and Co-Founder of TFives, reflects on a significant learning experience where an AI solution for detecting adverse drug reactions, despite achieving 85% accuracy, faced an 18-month delay due to compliance issues. This situation underscored a fundamental challenge in regulated environments: successful models can become liabilities without proper evidence and audit trails. Mohapatra advocates for a shift from viewing compliance as a final checkpoint to embedding it into the foundational architecture of product development.
This proactive approach, termed "compliance-by-design," emphasizes the importance of capturing evidence throughout the development process rather than reconstructing it post-factum. By integrating governance into every decision and workflow, organizations can create a continuous record that supports regulatory requirements. Mohapatra highlights that this method allows for real-time compliance, reducing delays and fostering a culture where validation is part of daily operations.
Moreover, the challenge of aligning probabilistic AI outcomes with deterministic regulatory frameworks is crucial. Regulatory bodies expect consistency and traceability, which can be achieved by maintaining detailed records of AI decisions, approvals, and the underlying rules. Mohapatra argues that organizations must embrace this complexity, positioning human oversight at the core of AI workflows to ensure accountability and transparency.
Ultimately, the lesson learned from the costly compliance failure is clear: innovation in life sciences will thrive when evidence and governance are integral to AI development. As the industry shifts towards a model where regulatory compliance is seen as a strategic advantage, companies that adapt to these requirements will likely lead the way in the future of life sciences.